Oxybutynine Eg (Oxybutynin Hydrochloride)

Oxybutynin Hydrochloride, the active ingredient in Oxybutynine Eg, is an antispasmodic presented as a tablet for oral use. It treats urinary incontinence by reducing involuntary bladder muscle contractions in adults.

GNH USA supplies Oxybutynine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxybutynine Eg is an antispasmodic that acts on the urinary tract smooth muscle to improve bladder control. - Overactive bladder: reduces urgency and frequency of urination. - Urge urinary incontinence: lessens the amount of leakage. - Neurogenic bladder dysfunction: helps manage involuntary bladder contractions.

Adverse reactions to oxybutynin vary in frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary flow. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient visual accommodation changes. - Drowsiness: mild central nervous system sedation. - Urinary retention: difficulty initiating voiding.

Serious or Rare Side Effects: - Tachycardia: rapid heart rate that may require monitoring. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Angle‑closure glaucoma: acute eye pain and visual disturbance. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Urinary retention leading to acute urinary obstruction.

When prescribing oxybutynin, clinicians should consider several safety aspects. - Assess renal and hepatic function: dose may need adjustment in impairment. - Review cardiac history: monitor for tachycardia or arrhythmias. - Evaluate glaucoma risk: avoid in patients with narrow‑angle glaucoma. - Counsel on anticholinergic burden: caution in elderly patients prone to confusion. - Monitor for urinary retention: advise patients to report difficulty voiding. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxybutynin may interact with other medications that influence anticholinergic load or cardiac conduction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase oxybutynin plasma levels. - QT‑prolonging agents (e.g., sotalol, quinidine): additive risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Other anticholinergics (e.g., diphenhydramine, ipratropium): heightened anticholinergic side effects. - Beta‑blockers: may mask tachycardia. - Digoxin: potential increase in serum digoxin concentration. - Alcohol: may intensify drowsiness and dizziness. - Antihistamines: additive dry‑mouth effect.